PACAP38 Induced Headache, Migraine and Flushing in Patients With Migraine

• Status: Completed
• Trial end date: 2019-12-07
• Target enrollment: 0
• Participant gender: All

Summary

The aim is to investigate the incidence of headache, migraine attacks and flushing after pituitary adenylate cyclase-activating peptide-38 (PACAP38) with and without treatment with sumatriptan in patients with migraine

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Danish Headache Center
• Treatments: Pituitary Adenylate Cyclase-Activating Polypeptide; Sumatriptan

Criteria

Inclusion Criteria:

• diagnosis of migraine, according to IHS criteria

• weight between 50 - 100 kilograms

• women in fertile age must not be pregnant and must use adequate contraception

Exclusion Criteria:

• migraine more than 5 days per month in average over the past year

• any primary headache other than migraine, apart from tension-type headache which must be less than 5 days per month

• headache < 48 hours before experimental day

• migraine < 72 hours before each experimental day

• daily / frequent use of any medication apart from contraceptive medication

• use of any drug less than 5 times the half-life of the drug at the time of the experiment

• women who are pregnant or breast-feeding at the time of the experiment

• anamnestic or clinical signs of hypertension (systolic blood pressure > 150 mmHg and/or

• diastolic blood pressure > 100 mmHg) or hypotension (systolic blood pressure < 90 mmHg and/or diastolic blood pressure < 50 mmHg)

• anamnestic or clinical signs of mental illness, or abuse of alcohol / drugs

• patients with glaucoma or prostate hyperplasia

• anamnestic or clinical symptoms of any sort that the investigating doctor deemed unfit for participating in the study